- Home
- NBH vs TNGX Comparison
NBH vs TNGX Comparison
Compare NBH & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- TNGX
- Stock Information
- Founded
- NBH 2002
- TNGX 2014
- Country
- NBH United States
- TNGX United States
- Employees
- NBH N/A
- TNGX N/A
- Industry
- NBH Finance/Investors Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NBH Finance
- TNGX Health Care
- Exchange
- NBH Nasdaq
- TNGX Nasdaq
- Market Cap
- NBH 317.5M
- TNGX 317.4M
- IPO Year
- NBH N/A
- TNGX N/A
- Fundamental
- Price
- NBH $10.37
- TNGX $1.37
- Analyst Decision
- NBH
- TNGX Strong Buy
- Analyst Count
- NBH 0
- TNGX 7
- Target Price
- NBH N/A
- TNGX $12.33
- AVG Volume (30 Days)
- NBH 85.9K
- TNGX 789.1K
- Earning Date
- NBH 01-01-0001
- TNGX 05-07-2025
- Dividend Yield
- NBH 4.34%
- TNGX N/A
- EPS Growth
- NBH N/A
- TNGX N/A
- EPS
- NBH 0.12
- TNGX N/A
- Revenue
- NBH N/A
- TNGX $42,069,000.00
- Revenue This Year
- NBH N/A
- TNGX N/A
- Revenue Next Year
- NBH N/A
- TNGX N/A
- P/E Ratio
- NBH $87.04
- TNGX N/A
- Revenue Growth
- NBH N/A
- TNGX 15.17
- 52 Week Low
- NBH $8.75
- TNGX $1.33
- 52 Week High
- NBH $11.01
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- NBH 38.61
- TNGX 26.22
- Support Level
- NBH $10.30
- TNGX $1.48
- Resistance Level
- NBH $10.50
- TNGX $1.66
- Average True Range (ATR)
- NBH 0.08
- TNGX 0.16
- MACD
- NBH -0.01
- TNGX -0.01
- Stochastic Oscillator
- NBH 24.14
- TNGX 5.63
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.